Mackenzie Financial Corp Arrowhead Pharmaceuticals, Inc. Transaction History

Mackenzie Financial Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$27.21 - $39.48 $198,605 - $288,164	7,299 New	7,299 $208,000
Q2 2023 Aug 03, 2023	BUY	$25.16 - $41.38 $161,502 - $265,618	6,419 New	6,419 $228,000
Q4 2022 Feb 14, 2023	SELL	$28.0 - $40.56 $9,492 - $13,749	-339 Reduced 5.02%	6,419 $260,000
Q3 2022 Oct 07, 2022	SELL	$29.63 - $48.31 $11,674 - $19,034	-394 Reduced 5.51%	6,758 $223,000
Q2 2022 Aug 10, 2022	BUY	$27.79 - $50.61 $40,712 - $74,143	1,465 Added 25.76%	7,152 $252,000
Q1 2022 May 13, 2022	BUY	$39.62 - $69.97 $1,505 - $2,658	38 Added 0.67%	5,687 $262,000
Q4 2021 Feb 14, 2022	SELL	$58.09 - $82.51 $6,041 - $8,581	-104 Reduced 1.81%	5,649 $375,000
Q3 2021 Nov 08, 2021	BUY	$58.38 - $84.96 $138,243 - $201,185	2,368 Added 69.96%	5,753 $359,000
Q2 2021 Aug 11, 2021	BUY	$62.15 - $90.32 $210,377 - $305,733	3,385 New	3,385 $280,000
Q2 2019 Aug 14, 2019	SELL	$17.43 - $28.82 $266,679 - $440,946	-15,300 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $184,365 - $308,754	15,300 New	15,300 $281,000

294

90.8M

155K

426K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2.01B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Mackenzie Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Mackenzie Financial Corp with notifications on news.